Market Overview

Piper Jaffray Reiterates Overweight Rating, $103 PT on Watson Pharmaceuticals

Share:

In a report published Wednesday, Piper Jaffray & Co. reiterated its Overweight rating and $103.00 price target on Watson Pharmaceuticals (NYSE: WPI).

Piper Jaffray noted, “On Monday, Mallinckrodt (Covidien's pharma business) became the first filer to gain approval of a Concerta generic. While the approval comes as a surprise to us, Watson had long ago set expectations that a second entrant to the Concerta market would happen in 2013. WPI's guidance had already reflected one additional competitor in 1Q13, and most Street estimates (including ours) factor in further competition beyond 2013. With other high-value generics providing significant contribution (i.e. Lidoderm, Adderall XR) or providing the potential for longer-term upside (e.g., Intuniv), we continue to believe WPI earnings are still likely to approach $10 per share by 2014. With a 2014 P/E of 9x in the context of numerous high-value generics opportunities and compelling synergies from the Actavis transaction, we believe WPI shares are valued attractively. We reiterate our Overweight rating and $103 price target.”

Watson Pharmaceuticals closed on Monday at $86.00.

Latest Ratings for WPI

DateFirmActionFromTo
Jan 2013DowngradesBuyNeutral
Nov 2012MaintainsOutperform
Nov 2012UpgradesNeutralOverweight

View More Analyst Ratings for WPI
View the Latest Analyst Ratings

Posted-In: Piper Jaffray & Co.Analyst Color Reiteration Analyst Ratings

 

Related Articles (WPI)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MUCascendReiterates65.0
ALDRCanaccord GenuityDowngrades20.0
LEGHLake StreetInitiates Coverage On21.0
CHUGoldman SachsUpgrades13.2
STZBMO CapitalMaintains230.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

UPDATE: Piper Jaffray Reiterates Apple at Buy with $900 PT on Wearable Computer Thoughts

Piper Jaffray Reiterates Neutral Rating, $37 PT on Sohu.com